Skip to main content
Top
Published in: Diabetologia 4/2003

01-04-2003 | Short Communication

Norepinephrine release is reduced in cardiac tissue of Type 2 diabetic patients

Authors: C. Burgdorf, D. Richardt, T. Kurz, S. Adler, A. Nötzold, E. G. Kraatz, H. H. Sievers, G. Richardt

Published in: Diabetologia | Issue 4/2003

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to assess whether cardiac catecholamine release is affected in patients with Type 2 diabetes mellitus.

Methods

A trial tissue was obtained from 19 diabetic (Type 2) and 43 non-diabetic patients undergoing coronary surgery. Endogenous norepinephrine release was examined under baseline conditions as well as during electrical field stimulation (effective voltage 5 V, stimulation frequency 4 Hz, pulse width 2 msec) by high performance liquid chromatography and electrochemical detection. Cardiac function and arterial blood pressure was assessed from coronary angiography.

Results

In atrial tissue from diabetic patients, stimulation-induced norepinephrine release was reduced by 25% compared with non-diabetic patients, while baseline norepinephrine release did not differ between both groups. Preoperative plasma glucose and haemoglobin A1C concentrations were increased in patients with diabetes, however, no relation was found to catecholamine release. Diabetic and non-diabetic patients did not differ regarding left ventricular ejection fraction and arterial blood pressure.

Conclusion/interpretation

Cardiac norepinephrine release is suppressed in patients with Type 2 diabetes which could contribute to sympathetic neuropathy. The difference of norepinephrine release in diabetic and non-diabetic patients was independent of cardiac function and arterial blood pressure.
Literature
1.
go back to reference Stevens MJ, Raffel DM, Allman KC et al. (1998) Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 98:961–968PubMed Stevens MJ, Raffel DM, Allman KC et al. (1998) Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 98:961–968PubMed
2.
go back to reference Di Carli MF, Bianco-Batlles D, Landa ME et al. (1999) Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 100:813–819PubMed Di Carli MF, Bianco-Batlles D, Landa ME et al. (1999) Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 100:813–819PubMed
3.
go back to reference Schramm E, Wagner M, Nellessen U, Inselmann G (2000) Ultrastructural changes of human cardiac atrial nerve endings in diabetes mellitus. Eur J Clin Invest 30:311–316CrossRefPubMed Schramm E, Wagner M, Nellessen U, Inselmann G (2000) Ultrastructural changes of human cardiac atrial nerve endings in diabetes mellitus. Eur J Clin Invest 30:311–316CrossRefPubMed
4.
go back to reference Caviezel F, Picotti GB, Margonato A et al. (1982) Plasma adrenaline and noradrenaline concentrations in diabetic patients with and without autonomic neuropathy at rest and during sympathetic stimulation. Diabetologia 23:19–23PubMed Caviezel F, Picotti GB, Margonato A et al. (1982) Plasma adrenaline and noradrenaline concentrations in diabetic patients with and without autonomic neuropathy at rest and during sympathetic stimulation. Diabetologia 23:19–23PubMed
5.
go back to reference Colucci WS, Braunwald E (2001) Pathophysiology of heart failure. In: Braunwald E, Zipes DP, Libby P (eds) Heart disease: a textbook of cardiovascular medicine. 6th edn. WB Saunders, Philadelphia, pp 503–533 Colucci WS, Braunwald E (2001) Pathophysiology of heart failure. In: Braunwald E, Zipes DP, Libby P (eds) Heart disease: a textbook of cardiovascular medicine. 6th edn. WB Saunders, Philadelphia, pp 503–533
6.
go back to reference Münch G, Kurz T, Urlbauer T, Seyfarth M, Richardt G (1996) Differential presynaptic modulation of noradrenaline release in human atrial tissue in normoxia and anoxia. Br J Pharmacol 118:1855–1861PubMed Münch G, Kurz T, Urlbauer T, Seyfarth M, Richardt G (1996) Differential presynaptic modulation of noradrenaline release in human atrial tissue in normoxia and anoxia. Br J Pharmacol 118:1855–1861PubMed
7.
go back to reference Gando S, Hattori Y, Kanno M (1993) Altered cardiac adrenergic neurotransmission in streptozotocin-induced diabetic rats. Br J Pharmacol 109:1276–1281PubMed Gando S, Hattori Y, Kanno M (1993) Altered cardiac adrenergic neurotransmission in streptozotocin-induced diabetic rats. Br J Pharmacol 109:1276–1281PubMed
8.
go back to reference Tesfamariam B, Cohen RA (1995) Enhanced adrenergic neurotransmission in diabetic rabbit carotid artery. Cardiovasc Res 29:549–554CrossRefPubMed Tesfamariam B, Cohen RA (1995) Enhanced adrenergic neurotransmission in diabetic rabbit carotid artery. Cardiovasc Res 29:549–554CrossRefPubMed
9.
go back to reference Hashimoto H, Satoh N, Takiguchi Y, Nakashima M (1990) Effects of an aldose reductase inhibitor, ONO-2235, insulin and their combination on the altered responsiveness to the nerve stimulation and agonists of the isolated atria of diabetic rats. J Pharmacol Exp Ther 253:552–557 Hashimoto H, Satoh N, Takiguchi Y, Nakashima M (1990) Effects of an aldose reductase inhibitor, ONO-2235, insulin and their combination on the altered responsiveness to the nerve stimulation and agonists of the isolated atria of diabetic rats. J Pharmacol Exp Ther 253:552–557
10.
go back to reference Scognamiglio R, Avogaro A, Casara D et al. (1998) Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 31:404–412CrossRefPubMed Scognamiglio R, Avogaro A, Casara D et al. (1998) Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 31:404–412CrossRefPubMed
Metadata
Title
Norepinephrine release is reduced in cardiac tissue of Type 2 diabetic patients
Authors
C. Burgdorf
D. Richardt
T. Kurz
S. Adler
A. Nötzold
E. G. Kraatz
H. H. Sievers
G. Richardt
Publication date
01-04-2003
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2003
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1055-2

Other articles of this Issue 4/2003

Diabetologia 4/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.